ERBB2 and neoplasm: The possibility of predicting patients with a less unfavorable tumor histotype (i.e., ER- and PR-positive patients or patients with a low expression of Ki-67) or unfavorable tumor histotype (e.g., patients that are HER2+) before a biopsy could be revolutionary in clinical settings.